Loading...
•
Mar 31, 2024
Krystal Biotech Q1 2024 Earnings Report
Reported first quarter financial results and provided business updates.
Key Takeaways
Krystal Biotech reported strong uptake of VYJUVEK and progress across its clinical pipeline in Q1 2024. Net product revenue was $45.3 million, and the company has $622.3 million in cash and investments.
Net product revenue of $45.3 million in 1Q and $95.9 million since August.
First patient dosed in inhaled KB707 study for locally advanced or metastatic tumors of the lung.
Received Fast Track Designations for both inhaled and intratumoral KB707.
Strong balance sheet with $622.3 million in cash and investments.
Krystal Biotech
Krystal Biotech
Forward Guidance
The company anticipates approximately $150 million to $175 million of Non-GAAP Research and Development and Selling, General and Administrative expense for the year ending December 31, 2024.